Drug class in one race
PD-L1 drugs for Non-Small Cell Lung Cancer
11 tracked PD-L1 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the PD-L1 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
3 approved / phase 44 Phase 31 Phase 2/31 Phase 22 Phase 1
Head-to-head evidence: 177Lu-RAD204 vs Atezolizumab · 177Lu-RAD204 vs CS1001 Monoclonal Antibody · 177Lu-RAD204 vs Durvalumab · 177Lu-RAD204 vs Envafolimab · 177Lu-RAD204 vs Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) · Adebrelimab vs Atezolizumab